Switching anti-CGRP(R) monoclonal antibodies in multi-assessed non-responder patients and implications for ineffectiveness criteria: A retrospective cohort study.

Luigi Francesco IannoneAndrea BurgalassiGiulia ViganiGiorgio TabassoFrancesco De CesarisAlberto ChiarugiPierangelo Geppetti

Published in: Cephalalgia : an international journal of headache (2023)

Switching anti-calcitonin gene related peptide monoclonal antibodies in selected patients might be an option to achieve or improve clinical benefit. More studies are required to establish the effectiveness of switching these treatments.

Keyphrases

end stage renal disease
ejection fraction
newly diagnosed
chronic kidney disease
randomized controlled trial
systematic review
peritoneal dialysis
prognostic factors
dna methylation
transcription factor